Advances in pediatric solid tumor immunotherapy based on chimeric antigen receptor T cell
10.3760/cma.j.issn.1673-4408.2022.04.005
- VernacularTitle:基于嵌合抗原受体T细胞的儿童实体肿瘤免疫治疗研究进展
- Author:
Wenjie LI
1
;
Benshang LI
Author Information
1. 上海交通大学医学院附属上海儿童医学中心血液肿瘤科 200127
- Keywords:
Children;
Chimeric antigen receptor T cell;
Immunotherapy;
Target;
Tumor microenvironment
- From:
International Journal of Pediatrics
2022;49(4):236-240
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor T cell immunotherapy(CAR-T)has achieved a significant breakthrough in hematologic malignancies.On the contrary, the application of CAR-T in solid tumor, including pediatric solid tumor, is confronted with numerous barriers.Pre-clinical experiments and clinical trials point out that several reasons account for the consequence: rare and heterogeneous targets; limited lifetime of CAR-T in vivo as a result of T cell exhaustion; inadequate infiltration of tumor sites due to steric hindrance; side effects of treatment.Based on the above problems, this review will summarize the research progression of different targets, the choice of immune cells, inhibitory tumor microenvironment, and countermeasures for side effects, so as to provide several new explorable directions for improving the treatment effect.
